Skip to main content
Premium Trial:

Request an Annual Quote

Gene Bridges Inks License with Japanese Pharma Firm

NEW YORK (GenomeWeb News) – German genetic engineering company Gene Bridges said today that it has licensed its DNA recombination technology to Japanese pharmaceutical firm Daiichi Sankyo.

The company said that the technology, which is patented in Japan as a "Novel DNA Cloning Method," is used to generate targeting vectors or for modifying E. coli chromosomes.

The Heidelberg-based company's RedET technology allows cloning, subcloning, and DNA modification at chosen positions, and it enables engineering of large DNA molecules, such as BACs and E. coli.

Funakoshi serves as Gene Bridges' distribution partner in Japan.

Financial terms of the agreement were not released.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.